Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

March 2024

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial

Lancet 2024;403(10429):850–859 doi 10.1016/S0140-6736(23)02650-8

Rech J,

Hagen M,

Braun J,

Kiltz U,

Fleck M,

Voll R,

Thiel J,

Feist E,

Largo R,

This study by Rech, et al. shows that 6-month treatment with abatacept was associated with a decrease in MRI inflammation, clinical symptoms, and risk of RA development in participants at high risk. The effects of the intervention persist through a 1-year drug-free observation phase.

Keywords:

July 2020

COVID-19 Revisitando as vias inflamatórias na artrite

Nat Rev Rheumatol 2020 doi.org/10.1038/s41584-020-0451-z

Schett G,

Manger B,

Simon D,

Caporali R

This review investigates the potential implications of COVID-19 on the field of rheumatology. Common pathways in COVID-19 and RA have provided rationale for the trial of DMARD therapies in treatment of severe COVID-19 infections. Safety considerations of RA patients undergoing immunomodulatory treatments are reviewed. Recommendations suggest that RA patients should continue DMARD treatment, whereas glucocorticoid use could be deleterious in COVID-19 infection and should be considered carefully, ...